CL2015000744A1 - Combinación de regorafenib y ácido acetilsalicílico para el tratamiento del cáncer. - Google Patents

Combinación de regorafenib y ácido acetilsalicílico para el tratamiento del cáncer.

Info

Publication number
CL2015000744A1
CL2015000744A1 CL2015000744A CL2015000744A CL2015000744A1 CL 2015000744 A1 CL2015000744 A1 CL 2015000744A1 CL 2015000744 A CL2015000744 A CL 2015000744A CL 2015000744 A CL2015000744 A CL 2015000744A CL 2015000744 A1 CL2015000744 A1 CL 2015000744A1
Authority
CL
Chile
Prior art keywords
regorafenib
combination
cancer treatment
acetylsalicylic acid
treatment
Prior art date
Application number
CL2015000744A
Other languages
English (en)
Inventor
Olaf Weber
Karl Ziegelbauer
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46963566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015000744(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of CL2015000744A1 publication Critical patent/CL2015000744A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMBINACION FARMACEUTICA QUE COMPRENDE REGORAFENIB Y ACIDO ACETILSALICILICO O UN HIDRATO, UN SOLVATO, UN METABOLITO, UNA SAL O UN POLIMORFO DE LOS MISMOS; Y PROCEDIMIENTO DE TRATAMIENTO DE TRASTORNOS PROLIFERATIVOS.
CL2015000744A 2012-09-25 2015-03-24 Combinación de regorafenib y ácido acetilsalicílico para el tratamiento del cáncer. CL2015000744A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12185852 2012-09-25

Publications (1)

Publication Number Publication Date
CL2015000744A1 true CL2015000744A1 (es) 2016-01-08

Family

ID=46963566

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015000744A CL2015000744A1 (es) 2012-09-25 2015-03-24 Combinación de regorafenib y ácido acetilsalicílico para el tratamiento del cáncer.

Country Status (29)

Country Link
US (1) US10898500B2 (es)
EP (1) EP2900269B1 (es)
JP (1) JP6294888B2 (es)
KR (1) KR102210575B1 (es)
CN (1) CN104994876A (es)
AU (1) AU2013322854B2 (es)
BR (1) BR112015006686B1 (es)
CA (1) CA2885688C (es)
CL (1) CL2015000744A1 (es)
CY (1) CY1120939T1 (es)
DK (1) DK2900269T3 (es)
EA (1) EA032023B1 (es)
ES (1) ES2687985T3 (es)
HK (1) HK1214169A1 (es)
HR (1) HRP20181462T1 (es)
HU (1) HUE039878T2 (es)
IL (1) IL237690B (es)
LT (1) LT2900269T (es)
MX (1) MX357035B (es)
MY (1) MY183969A (es)
NZ (1) NZ705860A (es)
PH (1) PH12015500587A1 (es)
PL (1) PL2900269T3 (es)
PT (1) PT2900269T (es)
RS (1) RS57875B1 (es)
SG (2) SG11201501963RA (es)
SI (1) SI2900269T1 (es)
WO (1) WO2014048881A1 (es)
ZA (1) ZA201502840B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014DN09346A (es) 2012-06-13 2015-07-17 Hoffmann La Roche
KR102179599B1 (ko) 2012-09-25 2020-11-19 에프. 호프만-라 로슈 아게 이환형 유도체
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
CN105764905B (zh) 2013-11-26 2019-06-07 豪夫迈·罗氏有限公司 新的八氢-环丁二烯并[1，2-c；3，4-c’]二吡咯-2基
WO2015144609A1 (en) 2014-03-26 2015-10-01 F. Hoffmann-La Roche Ag Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
CN106103446B (zh) 2014-03-26 2019-07-30 豪夫迈·罗氏有限公司 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的二环化合物
CN104829523B (zh) * 2014-04-30 2017-10-31 药源药物化学（上海）有限公司 瑞戈非尼盐及其晶型、制备方法
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
CA2992889A1 (en) 2015-09-04 2017-03-09 F. Hoffmann-La Roche Ag Phenoxymethyl derivatives
CN105267167A (zh) * 2015-09-11 2016-01-27 江苏嘉逸医药有限公司 一种瑞戈非尼口服固体药物组合物的制备方法
CR20180057A (es) 2015-09-24 2018-04-02 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores duales de atx/ca.
RU2018112230A (ru) 2015-09-24 2019-10-30 Ф. Хоффманн-Ля Рош Аг Бициклические соединения в качестве ингибиторов atx
KR20180054830A (ko) 2015-09-24 2018-05-24 에프. 호프만-라 로슈 아게 오토탁신(atx) 억제제로서의 이환형 화합물
AU2016328365B2 (en) 2015-09-24 2020-04-23 F. Hoffmann-La Roche Ag New bicyclic compounds as dual ATX/CA inhibitors
WO2018002124A1 (en) * 2016-06-28 2018-01-04 Asamedic As Two-component composition
SG11201908560SA (en) 2017-03-16 2019-10-30 Hoffmann La Roche Heterocyclic compounds useful as dual atx/ca inhibitors
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
PE20200859A1 (es) * 2017-06-02 2020-08-25 Bayer Healthcare Llc Combinacion farmaceutica que comprende regonafenib y nivolumab como anticancerigeno
EP3501522A1 (en) 2017-12-22 2019-06-26 Asamedic AS Compositions comprising acetylsalicylic acid and a phosphate salt
EP3501523A1 (en) 2017-12-22 2019-06-26 Asamedic AS Two-component compositions comprising acetyl salicylic acid and a carbonate salt
KR20210156389A (ko) 2020-06-17 2021-12-27 재단법인대구경북과학기술원 레고라페닙을 유효성분으로 포함하는 염증질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1197228A4 (en) * 1999-07-02 2004-03-10 Hisamitsu Pharmaceutical Co DRUG COMPOSITIONS FOR THE TREATMENT OF COLORECTAL CANCER
US20040121004A1 (en) 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
EA010485B1 (ru) * 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
JP2009514921A (ja) * 2005-11-10 2009-04-09 バイエル・ヘルスケア・アクチェンゲゼルシャフト 糖尿病性神経障害を処置するためのジアリールウレア
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
GB201002530D0 (en) * 2010-02-15 2010-03-31 Univ Wolverhampton The Di-aspirin derivatives
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida

Also Published As

Publication number Publication date
SI2900269T1 (sl) 2018-10-30
IL237690B (en) 2019-07-31
LT2900269T (lt) 2018-11-12
IL237690A0 (en) 2015-05-31
KR20150060869A (ko) 2015-06-03
JP6294888B2 (ja) 2018-03-14
MX2015003728A (es) 2015-09-23
DK2900269T3 (en) 2018-10-01
HRP20181462T1 (hr) 2018-11-02
EA032023B1 (ru) 2019-03-29
AU2013322854B2 (en) 2018-07-19
AU2013322854A1 (en) 2015-04-02
CA2885688A1 (en) 2014-04-03
ZA201502840B (en) 2017-11-29
HK1214169A1 (zh) 2016-07-22
US10898500B2 (en) 2021-01-26
CA2885688C (en) 2021-03-02
PT2900269T (pt) 2018-10-22
EP2900269B1 (en) 2018-08-01
EP2900269A1 (en) 2015-08-05
KR102210575B1 (ko) 2021-02-02
WO2014048881A1 (en) 2014-04-03
US20150202214A1 (en) 2015-07-23
CN104994876A (zh) 2015-10-21
SG10201702356VA (en) 2017-04-27
NZ705860A (en) 2018-07-27
ES2687985T3 (es) 2018-10-30
HUE039878T2 (hu) 2019-02-28
JP2015529234A (ja) 2015-10-05
BR112015006686B1 (pt) 2022-04-05
EA201500365A1 (ru) 2015-08-31
SG11201501963RA (en) 2015-04-29
PL2900269T3 (pl) 2019-02-28
RS57875B1 (sr) 2018-12-31
MX357035B (es) 2018-06-25
CY1120939T1 (el) 2019-12-11
BR112015006686A2 (pt) 2019-08-27
MY183969A (en) 2021-03-17
PH12015500587A1 (en) 2015-05-11

Similar Documents

Publication Publication Date Title
CL2015000744A1 (es) Combinación de regorafenib y ácido acetilsalicílico para el tratamiento del cáncer.
NI201600058A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
SV2016005137A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
GT201500053A (es) Composicion farmaceutica recubierta que contiene regorafenib
SV2015005066A (es) Compuestos de biaril-amida como inhibidores de cinasa
CL2017002786A1 (es) Referencia cruzada a solicitudes relacionadas
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
MX2019010422A (es) Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacionados con la fosfoinositida 3-cinasa delta.
CU20160052A7 (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
NI201600071A (es) Compuestos de inhibidor de autotaxina
GEAP202114132A (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
ECSP17013903A (es) Protein kinase c inhibitors and methods of their use
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
BR112016027041A2 (pt) Combinações farmacêuticas para tratamento do câncer
CU20160192A7 (es) Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
DK3258938T3 (da) Phenothiazinanaloger som mitokondrie terapeutiske midler
CL2016001587A1 (es) Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
SV2016005313A (es) Derivados de carboxamida
UY36292A (es) Compuestos de tetrahidroquinolina para su uso como inhibidores de bromodominios
UY34786A (es) Procedimiento para la fabricación de una forma farmacéutica que comprende nifedipino y candesartan cilexetilo
UY35823A (es) Profármacos de antagonista de nmda